Following publication of the original version of this article (1), a resynthesis and reevaluation of a fresh lot of our lead compound AGF347 afforded improved in vitro biological activity from that originally published. Examination of the original sample of AGF347 used for the in vitro enzyme assays via LC/MS indicated 65% purity at the time these experiments were performed. The origin of the impurity (e.g., contamination or degradation) is unknown. Data collected for serine hydroxymethyl transferase (SHMT) 1 and SHMT2 inhibition assays were impacted by the impure sample such that the original reported Ki values of 2.91 μmol/L (±0.59 SD) for SHMT1 and 2.19 μmol/L (±0.23) for SHMT2 decreased to 1.25 μmol/L (±0.43) for SHMT1 and 0.45 μmol/L (±0.19) for SHMT2 when assays were performed with a separate lot of AGF347 measured at > 98% purity. As all of the other in vitro and in vivo experiments described in the manuscript used AGF347 at >98% purity, these results are correct as originally reported.

1.
Dekhne
AS
,
Shah
K
,
Ducker
GS
,
Katinas
JM
,
Wong-Roushar
J
,
Nayeen
MJ
, et al
.
Novel Pyrrolo[3,2-d]pyrimidine compounds target mitochondrial and cytosolic one-carbon metabolism with broad-spectrum antitumor efficacy
.
Mol Cancer Ther
2019
;
18
:
1787
99
.